This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
StatPearls [Internet].
Show detailsContinuing Education Activity
According to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), somatic symptom disorder (SSD) involves one or more physical symptoms accompanied by an excessive amount of time, energy, emotion, and/or behavior related to the symptom that results in significant distress and/or dysfunction. Physical symptoms may or may or may not be explained by a medical condition. In previous editions of the Diagnostic and Statistical Manual of Mental Disorders, the diagnosis of somatic symptom disorder could not be made unless somatic symptoms were not able to be explained clinically. Additionally, previous editions did not include the requirement that certain psychobehavioral features be present for the diagnosis of somatic symptom disorder to be made. The DSM-5 also removed somatization disorder, undifferentiated somatoform disorder, hypochondriasis, and pain disorder. Many patients that historically met the criteria for one of those conditions now meet criteria for SSD, based on these revisions. This activity reviews the presentation, evaluation, and management of SSD and stresses the interprofessional team approach to the care of affected patients.
Objectives:
- Describe somatic symptom disorder.
- Review the epidemiology of somatic symptom disorder.
- Explain how to effectively manage a patient with somatic symptom disorder.
- Outline modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by somatic symptom disorder.
Introduction
Somatic symptom disorder (SSD) is a recently defined diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). It is the manifestation of one or more physical symptoms accompanied by excessive thoughts, emotion, and/or behavior related to the symptom, which causes significant distress and/or dysfunction.[1] These symptoms may or may not be explained by a medical condition. The two major changes to the DSM-IV criteria included eliminating the requirement that somatic symptoms be organically unexplained and adding the requirement that certain psychobehavioral features have to be present to justify the diagnosis. The new criteria also eliminated somatization disorder, undifferentiated somatoform disorder, hypochondriasis, and pain disorder from the previous definitions. These revisions were intended to increase the relevance of SSD and its use in the primary care setting.
Etiology
Somatic symptom disorder (SSD) arises from a heightened awareness of various bodily sensations, which are combined with an inclination to interpret these sensations as indicative of medical illness. While the etiology of SSD is unclear, studies have investigated risk factors including childhood neglect, sexual abuse, chaotic lifestyle, and history of alcohol and substance abuse.[1] Furthermore, severe somatization has been associated with axis II personality disorders, particularly avoidant, paranoid, self-defeating, and obsessive-compulsive disorder.[2] Psychosocial stressors, including unemployment and impaired occupational functioning, have also been implicated.[3]
Epidemiology
The prevalence of somatic symptom disorder (SSD) is estimated to be 5% to 7% of the general population, with higher female representation (female-to-male ratio 10:1), and can occur in childhood, adolescence, or adulthood.[1][3] The prevalence increases to approximately 17% of the primary care patient population.[4] The prevalence is likely higher in certain patient populations with functional disorders, including fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome.[5]
Pathophysiology
The pathophysiology of somatic symptom disorder (SSD) is unknown. Autonomic arousal from endogenous noradrenergic compounds may cause tachycardia, gastric hypermotility, heightened arousal, muscle tension, and pain associated with muscular hyperactivity in patients with SSD. There may also be a genetic component. A study of monozygotic and dizygotic twins revealed that the contribution of genetic factors to somatic symptoms was 7% to 21%, while the remaining was attributable to environmental factors.[6] Several single nucleotide polymorphisms were associated with somatic symptoms in another study.[7]
History and Physical
Three requirements fulfill the diagnostic criteria for somatic syndrome disorders (SSDs) according to the American Psychiatric Association's 2013 DSM-5:
- Somatic symptom(s) that cause significant distress or disruption in daily living
- One or more thoughts, feelings, and/or behaviors that are related to the somatic symptom(s) which are persistent, excessive, associated with a high level of anxiety, and results in the devotion of excessive time and energy
- Symptoms lasting for more than 6 months
The presence of SSD may be suggested by a vague and often inconsistent history of present illness, symptoms that are rarely alleviated with medical interventions, patient attribution of normal sensations as medical illness, avoidance of physical activity, high sensitivity to medication adverse effects, and medical care from multiple providers for the same complaints.
In addition to a thorough history, a full review of systems (not only at the location of the symptom) and a comprehensive physical exam is required to evaluate physical causes of somatic complaints. Given frequent comorbid psychiatric disease, a mental status examination should be performed, noting appearance, mood, affect, attention, memory, concentration, orientation, the presence of hallucinations or delusions, and suicidal or homicidal ideation.[8] Ultimately, the physical examination may provide a baseline for monitoring over time, assure patients that their complaints are acknowledged, and help validate the primary care provider’s concern that the patient does not have a physical medical illness. If a disease is present, the exam may provide information on severity.
Evaluation
Limited laboratory testing is recommended as it is common for patients with somatic syndrome disorder (SSD) to have had a thorough prior workup. Excessive testing introduces the risk of false-positive results, which can subsequently lead to additional interventional procedures, its associated risks, and increased costs. While some clinicians order tests to provide reassurance to the patient, studies reveal that such diagnostic testing does not alleviate SSD symptoms. A meta-analysis by Rolfe and colleagues compared diagnostic testing versus a non-testing control condition, demonstrated that resolution of somatic symptoms and reduction of illness concern and anxiety was comparable between both groups. There was only a modest decrease in subsequent visits in the group that received diagnostic testing.[9]
If it is necessary to rule out somatization due to medical conditions, specific studies may be ordered, including but not limited to thyroid function tests, urine drug screen, limited blood studies (i.e., alcohol level), and limited radiological testing.
Treatment / Management
The primary objective is to help the patient cope with physical symptoms, including health anxiety and maladaptive behaviors, as opposed to eliminating the symptoms. Caution must be exercised when conveying to patients that their physical symptoms are exacerbated by anxiety or excessive emotional problems as patients may be resistant to this suggestion. The primary care provider should schedule regular visits to reinforce that symptoms are not suggestive of a life-threatening or disabling medical condition.[10] Diagnostic procedures and invasive surgical treatment are not recommended. Sedative medications, including benzodiazepines and narcotic analgesics, are avoided. Early psychiatric treatment is recommended. Studies have shown that cognitive-behavioral therapy is associated with significant improvement in patient-reported functioning and somatic symptoms, a decrease in health care costs,[11] and a reduction in depressive symptoms.[12] Pharmacologic approaches should be limited, but antidepressants can be initiated to treat psychiatric comorbidities (anxiety, depressive symptoms, obsessive-compulsive disorder). Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have shown efficacy with an improvement of SSD compared to placebo.[13] However, medications should be initiated at the lowest dose and increased slowly to achieve a therapeutic effect as patients with SSD may have a low threshold for perceiving adverse effects, introducing another source of concern.
Differential Diagnosis
The diffuse, non-specific symptoms in somatic syndrome disorder (SSD) may confound and mimic presentations of other medical illnesses, making diagnosis and treatment difficult. Excessive and disproportionate emotional and behavioral responses may be present in adjustment disorder, body dysmorphic disorder, obsessive-compulsive disorder, and illness anxiety disorder. Other functional disorders of unclear etiology, including fibromyalgia and irritable bowel syndrome, do not typically manifest with excessive thoughts, emotions, or maladaptive behavior.
Prognosis
Longitudinal studies show considerable chronicity, with up to 90% of somatic syndrome disorder (SSD) cases lasting longer than 5 years.[14][15] Systematic reviews and meta-analyses have revealed that therapeutic interventions only yield small-to-moderate effect sizes.[16][17] Chronic limitation of general function, significant psychological disability, and decreased quality of life are frequently observed.[15][18]
Complications
Alcohol and drug abuse are frequently observed,[19] and sometimes utilized to alleviate symptoms, increasing the risk of dependence on controlled substances. If the provider decides to pursue invasive diagnostic procedures or surgical interventions, iatrogenic complications may arise.
Consultations
Evaluation by a psychiatrist is beneficial to diagnose accompanying mood disorders.
Deterrence and Patient Education
The provider should acknowledge the patient’s symptoms and suffering and offer frequent follow-up evaluations. Patients should primarily discuss any somatic symptoms with their primary care provider, who will assess the need for subspecialty evaluation. Prompt treatment of psychiatric comorbidities and addressing life stressors may improve somatic symptoms. The education of family members is often necessary. Family members should spend time with patients, particularly when symptoms are absent, to avoid reinforcing the idea that symptoms bring special attention from others.[20]
Pearls and Other Issues
As suggested by Frances et al., the diagnostic criteria of somatic syndrome disorders (SSDs) are liberal and easy to meet. If a patient has a medical illness that causes excessive worry, they may be diagnosed with SSD based on DSM-V criteria. Furthermore, these criteria are subjective, unreliable, and may predispose the provider to pursue an incomplete diagnostic workup, potentially missing underlying medical or psychiatric illnesses.[21] The previous concern with the DSM-IV criteria was that it was too restrictive and stringent; for instance, to meet criteria for somatoform disorder per DSM-IV, one would have to report four distinct pain symptoms, two gastrointestinal symptoms, one sexual or reproductive symptom other than pain, and one pseudoneurological complaint.[22] However, in the effort to define criteria that are more utilized in the clinical setting, the DSM-V work group may have set definitions with high sensitivity but low specificity, capturing 7% of healthy people.[21] Frances et al. proposed changes to reduce false-positive overdiagnosis. Firstly, for patients with a medical illness, the reaction would have to be specified as “maladaptive,” “extreme,” “intrusive,” “impairing,” and “grossly in excess” compared to the expected reaction. These specific words may reduce the misdiagnosis in patients who have adaptive vigilance of their health concerns. In those with no diagnosed medical illness, there would have to be adequate and repeated medical workups at suitable intervals to uncover medical conditions that may present with time. The final suggested criterion is to rule out psychiatric disorders, particularly panic, generalized anxiety, and depression, as these disorders may manifest with physical symptoms.
Some providers find patients with SSD difficult to manage and often describe them in derogatory terms; the misconceived bias is that physical disorders are considered genuine, while those with SSD are inappropriately accused of manufacturing their symptoms. As an increasing primary care population with medically unexplained symptoms receives a diagnosis of SSD, there is a need to educate and train physicians about SSD, its significance, and how to best manage these patients.[23][24]
Enhancing Healthcare Team Outcomes
Making a diagnosis of somatic syndrome is not always easy. Healthcare providers, including nurse practitioners and primary care clinicians, should try and rule out organic disorders first before making a diagnosis of a somatic syndrome. Some healthcare providers find patients with SSD difficult to manage and often describe them in derogatory terms; the misconceived bias is that physical disorders are considered genuine, while those with SSD are inappropriately accused of manufacturing their symptoms. As an increasing primary care population with medically unexplained symptoms receives a diagnosis of SSD, there is a need to educate and train physicians about SSD, its significance, and how to best manage these patients.[23][24] When faced with a patient with somatic syndrome, a referral to a psychiatrist is highly recommended. The outlook for patients with somatic syndromes is guarded. Once diagnosis and treatment are initiated, the nurses and clinicians should coordinate the care and education of the patient and family to obtain the best outcomes. The syndrome is often chronic and can be associated with a poor quality of life. [Level 5]
Review Questions
References
- 1.
- Kurlansik SL, Maffei MS. Somatic Symptom Disorder. Am Fam Physician. 2016 Jan 01;93(1):49-54. [PubMed: 26760840]
- 2.
- Rost KM, Akins RN, Brown FW, Smith GR. The comorbidity of DSM-III-R personality disorders in somatization disorder. Gen Hosp Psychiatry. 1992 Sep;14(5):322-6. [PubMed: 1521787]
- 3.
- Harris AM, Orav EJ, Bates DW, Barsky AJ. Somatization increases disability independent of comorbidity. J Gen Intern Med. 2009 Feb;24(2):155-61. [PMC free article: PMC2629001] [PubMed: 19031038]
- 4.
- Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res. 2004 Apr;56(4):391-408. [PubMed: 15094023]
- 5.
- Häuser W, Bialas P, Welsch K, Wolfe F. Construct validity and clinical utility of current research criteria of DSM-5 somatic symptom disorder diagnosis in patients with fibromyalgia syndrome. J Psychosom Res. 2015 Jun;78(6):546-52. [PubMed: 25864805]
- 6.
- Kato K, Sullivan PF, Pedersen NL. Latent class analysis of functional somatic symptoms in a population-based sample of twins. J Psychosom Res. 2010 May;68(5):447-53. [PMC free article: PMC2858068] [PubMed: 20403503]
- 7.
- Holliday KL, Macfarlane GJ, Nicholl BI, Creed F, Thomson W, McBeth J. Genetic variation in neuroendocrine genes associates with somatic symptoms in the general population: results from the EPIFUND study. J Psychosom Res. 2010 May;68(5):469-74. [PMC free article: PMC2877873] [PubMed: 20403506]
- 8.
- Tylee A, Gandhi P. The importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry. 2005;7(4):167-76. [PMC free article: PMC1192435] [PubMed: 16163400]
- 9.
- Rolfe A, Burton C. Reassurance after diagnostic testing with a low pretest probability of serious disease: systematic review and meta-analysis. JAMA Intern Med. 2013 Mar 25;173(6):407-16. [PubMed: 23440131]
- 10.
- den Boeft M, Claassen-van Dessel N, van der Wouden JC. How should we manage adults with persistent unexplained physical symptoms? BMJ. 2017 Feb 08;356:j268. [PubMed: 28179237]
- 11.
- Allen LA, Woolfolk RL, Escobar JI, Gara MA, Hamer RM. Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. Arch Intern Med. 2006 Jul 24;166(14):1512-8. [PubMed: 16864762]
- 12.
- Beltman MW, Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomised controlled trials. Br J Psychiatry. 2010 Jul;197(1):11-9. [PubMed: 20592427]
- 13.
- Kleinstäuber M, Witthöft M, Steffanowski A, van Marwijk H, Hiller W, Lambert MJ. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev. 2014 Nov 07;2014(11):CD010628. [PMC free article: PMC11023023] [PubMed: 25379990]
- 14.
- Rief W, Rojas G. Stability of somatoform symptoms--implications for classification. Psychosom Med. 2007 Dec;69(9):864-9. [PubMed: 18040096]
- 15.
- Jackson JL, Kroenke K. Prevalence, impact, and prognosis of multisomatoform disorder in primary care: a 5-year follow-up study. Psychosom Med. 2008 May;70(4):430-4. [PubMed: 18434494]
- 16.
- Kleinstäuber M, Witthöft M, Hiller W. Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis. Clin Psychol Rev. 2011 Feb;31(1):146-60. [PubMed: 20920834]
- 17.
- van Dessel N, den Boeft M, van der Wouden JC, Kleinstäuber M, Leone SS, Terluin B, Numans ME, van der Horst HE, van Marwijk H. Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database Syst Rev. 2014 Nov 01;2014(11):CD011142. [PMC free article: PMC10984143] [PubMed: 25362239]
- 18.
- de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry. 2004 Jun;184:470-6. [PubMed: 15172939]
- 19.
- Hasin D, Katz H. Somatoform and substance use disorders. Psychosom Med. 2007 Dec;69(9):870-5. [PubMed: 18040097]
- 20.
- Chaturvedi SK, Desai G, Shaligram D. Somatoform disorders, somatization and abnormal illness behaviour. Int Rev Psychiatry. 2006 Feb;18(1):75-80. [PubMed: 16451884]
- 21.
- Frances A. DSM-5 somatic symptom disorder. J Nerv Ment Dis. 2013 Jun;201(6):530-1. [PubMed: 23719325]
- 22.
- Smith JK, Józefowicz RF. Diagnosis and treatment of somatoform disorders. Neurol Clin Pract. 2012 Jun;2(2):94-102. [PMC free article: PMC5798205] [PubMed: 29443321]
- 23.
- Chaturvedi SK. Many faces of somatic symptom disorders. Int Rev Psychiatry. 2013 Feb;25(1):1-4. [PubMed: 23383662]
- 24.
- Rask MT, Andersen RS, Bro F, Fink P, Rosendal M. Towards a clinically useful diagnosis for mild-to-moderate conditions of medically unexplained symptoms in general practice: a mixed methods study. BMC Fam Pract. 2014 Jun 12;15:118. [PMC free article: PMC4075929] [PubMed: 24924564]
Disclosure: Ryan D'Souza declares no relevant financial relationships with ineligible companies.
Disclosure: W Hooten declares no relevant financial relationships with ineligible companies.
- Continuing Education Activity
- Introduction
- Etiology
- Epidemiology
- Pathophysiology
- History and Physical
- Evaluation
- Treatment / Management
- Differential Diagnosis
- Prognosis
- Complications
- Consultations
- Deterrence and Patient Education
- Pearls and Other Issues
- Enhancing Healthcare Team Outcomes
- Review Questions
- References
- Review Briquet syndrome revisited: implications for functional neurological disorder.[Brain Commun. 2020]Review Briquet syndrome revisited: implications for functional neurological disorder.Maggio J, Alluri PR, Paredes-Echeverri S, Larson AG, Sojka P, Price BH, Aybek S, Perez DL. Brain Commun. 2020; 2(2):fcaa156. Epub 2020 Sep 23.
- Review [DSM-5: from 'somatoform disorders' to 'somatic symptom and related disorders'].[Tijdschr Psychiatr. 2014]Review [DSM-5: from 'somatoform disorders' to 'somatic symptom and related disorders'].van der Feltz-Cornelis CM, van Houdenhove B. Tijdschr Psychiatr. 2014; 56(3):182-6.
- Clinical value of DSM IV and DSM 5 criteria for diagnosing the most prevalent somatoform disorders in patients with medically unexplained physical symptoms (MUPS).[J Psychosom Res. 2016]Clinical value of DSM IV and DSM 5 criteria for diagnosing the most prevalent somatoform disorders in patients with medically unexplained physical symptoms (MUPS).Claassen-van Dessel N, van der Wouden JC, Dekker J, van der Horst HE. J Psychosom Res. 2016 Mar; 82:4-10. Epub 2016 Jan 12.
- Review Somatic Symptom Disorder and Health Anxiety: Assessment and Management.[Neurol Clin. 2023]Review Somatic Symptom Disorder and Health Anxiety: Assessment and Management.Sauer KS, Witthöft M, Rief W. Neurol Clin. 2023 Nov; 41(4):745-758. Epub 2023 Apr 20.
- Psychobehavioral B-Criteria of Somatic Symptom Disorder Are Associated with Somatic Symptom Reporting in a Large Sample of Psychosomatic Outpatients.[Complex Psychiatry. 2024]Psychobehavioral B-Criteria of Somatic Symptom Disorder Are Associated with Somatic Symptom Reporting in a Large Sample of Psychosomatic Outpatients.Hoheisel M, Popkirov S, Michaelis R, Rose M. Complex Psychiatry. 2024 Jan-Dec; 10(1-4):10-18. Epub 2024 Feb 7.
- Somatic Symptom Disorder - StatPearlsSomatic Symptom Disorder - StatPearls
- Ezetimibe - StatPearlsEzetimibe - StatPearls
- PREDICTED: Homo sapiens TATA-box binding protein associated factor 1 (TAF1), tra...PREDICTED: Homo sapiens TATA-box binding protein associated factor 1 (TAF1), transcript variant X12, mRNAgi|2217393929|ref|XM_047442402.1|Nucleotide
- transcription initiation factor TFIID subunit 1 isoform X15 [Homo sapiens]transcription initiation factor TFIID subunit 1 isoform X15 [Homo sapiens]gi|2462630655|ref|XP_054183617.1|Protein
- transcription initiation factor TFIID subunit 1 isoform X18 [Homo sapiens]transcription initiation factor TFIID subunit 1 isoform X18 [Homo sapiens]gi|2217393942|ref|XP_005262357.2|Protein
Your browsing activity is empty.
Activity recording is turned off.
See more...